We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.04 | 2.01 | 2.13 | 242,101 | 08:15:13 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -1.79 | 6.8M |
TIDMIMM
Immupharma PLC
09 July 2012
FOR IMMEDIATE RELEASE 9 July 2012
RNS REACH
IMMUPHARMA LAUNCHES NEW CORPORATE WEBSITE
PROVDING GREATER CLARITY ON LUPUZOR, CANCER AND ITS DEVELOPMENT PIPELINE
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug development company has today launched its new corporate website www.immupharma.com as part of its continued focus on improving how it communicates to investors, collaborators and potential licensing partners.
The new ImmuPharma website provides more detailed information about its two platform technologies and the Company's five lead compounds in development, each representing a potentially significant breakthrough in its field. This includes its lead product Lupuzor(TM), for the treatment of Lupus, which has recently received US FDA approval to enter Phase III with a Special Protocol Assessment and Fast Track designation and its cancer programme IPP-204106 which has a novel mechanism of action, aimed at preventing angiogenesis as well as proliferationand which was in May 2011 chosen to feature on the front cover of 'Cancer Research', the prestigious medical journal of the American Association for Cancer Research.
The website also provides more detail on ImmuPharma's key collaborator, Europe's largest fundamental research institution, the Centre National de la Recherche Scientifique (National Center for Scientific Research) or CNRS.
The website also includes an email alert service, for which shareholders are encouraged to register.
Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, commented:
"We are seeking to provide improved information in this new website, which includes more detailed content to give a comprehensive and accessible overview of ImmuPharma's investment strategy, key assets including our discovery pipeline and the collaborators we work with such as CNRS."
For further information please contact:
ImmuPharma PLC Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Lisa Baderoon, Head of Investor Relations +44 7721 413 496 Buchanan + 44 20 7466 5000 Mark Court
Website designed by Fruit Design
www.fruit-design.co.uk
Notes to Editors
ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company's most advanced drug candidate, Lupuzor(TM) a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation. ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABVLLBLDFFBBE
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
